If you take a compounded GLP-1, this is the most consequential development in the market since the shortage ended — and most patients have never heard of it.
On April 30, 2026, the US Food and Drug Administration announced it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, stating it found no clinical need for outsourcing facilities to compound them. The proposal was published in the Federal Register on May 1, 2026 with a 60-day comment period that closed on June 29, 2026.
Trade coverage described the move as the FDA seeking to permanently close the door on compounded GLP-1s. Reuters characterised it as proposing curbs on mass compounding of the Novo Nordisk and Eli Lilly weight-loss drugs. Stanford Medicine described it as the agency taking a sweeping step beyond its earlier actions.
This article explains what the 503B bulks list is, what the proposal would actually change, what it does not change, and what a patient currently on compounded medication should reasonably do about it.
What Happened, in Five Facts
April 1, 2026: The FDA Restated the Rules
The agency published a clarification reminding compounders that certain conditions must be met for compounded drugs to qualify for the exemptions under sections 503A and 503B. Reuters reported the agency saying compounders are permitted to produce copies of approved medicines only while those drugs are on the shortage list.
April 30, 2026: The Proposal
The FDA announced it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them.
May 1, 2026: Published in the Federal Register
The notice identifying the three bulk drug substances the FDA proposes not to include on the 503B Bulks List was published, opening a 60-day comment period.
June 29, 2026: Comments Closed
The federal comment period closed. A further Federal Register document dated June 26, 2026 relates to the same proposal. The FDA has not, at the time of writing, issued a final determination.
Neither Molecule Is on the Shortage List
The FDA has stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on the FDA drug shortage list — the two routes that previously made large-scale compounding straightforward.
What the 503B Bulks List Actually Is
Compounding pharmacies in the US fall into two broad categories, and the distinction matters here.
503A pharmacies compound against individual patient prescriptions and are regulated primarily by state boards of pharmacy. 503B outsourcing facilities register with the FDA, must comply with current good manufacturing practice requirements, may compound larger batches without patient-specific prescriptions, and are subject to FDA inspection. 503B is the tier that supplies compounded medication at scale.
A 503B facility can compound from a bulk drug substance in limited circumstances — broadly, when the substance appears on the FDA’s 503B bulks list, which identifies bulk drug substances for which there is a clinical need. The proposal published on May 1, 2026 identifies semaglutide, tirzepatide and liraglutide as three substances the FDA proposes not to include.
In plain terms: the agency is proposing to formally determine that there is no clinical need for outsourcing facilities to make these drugs, because approved versions are available.
This Is About Supply at Scale
The 503B tier is how compounded GLP-1s reached the volume they did. A determination of no clinical need targets the mechanism that made mass compounding possible in the first place.
The Shortage Route Already Closed
Compounders could previously make copies of approved drugs while those drugs were on the FDA shortage list. Semaglutide and tirzepatide have both left it, and the FDA has confirmed neither appears on the shortage list or the 503B bulks list.
Liraglutide Is Included Too
The proposal covers liraglutide alongside the two newer molecules. That matters for patients looking at compounded liraglutide as a route after Saxenda is discontinued in early 2027.
The Timeline That Got Us Here
The April 2026 proposal is the latest step in a sequence that has been running for roughly two years. Seeing it laid out makes the direction unmistakable.
| Date | What Happened |
|---|---|
| 2023–2024 | Semaglutide and tirzepatide on the FDA drug shortage list; compounded versions proliferate through telehealth |
| Feb 21, 2025 | FDA declares the semaglutide shortage resolved |
| Apr 22, 2025 | Deadline for 503A pharmacies to stop compounding semaglutide |
| May 22, 2025 | Deadline for 503B outsourcing facilities to stop compounding semaglutide |
| Sept 9, 2025 | FDA issues warning letters to telehealth companies including LumiMeds, citing misbranded compounded GLP-1 products |
| 2025 | FDA announces 30 warning letters to telehealth companies over false or misleading compounded GLP-1 claims |
| Apr 1, 2026 | FDA clarifies policies for compounders as national GLP-1 supply stabilises |
| Apr 30, 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list |
| May 1, 2026 | Proposal published in the Federal Register; 60-day comment period opens |
| Jun 29, 2026 | Comment period closes |
What This Does Not Mean
It is worth being precise, because there is a lot of loose commentary about this.
This is a proposal, not a final rule. The FDA sought comments, the comment period has closed, and the agency has not issued a final determination at the time of writing. Proposals can be modified or withdrawn.
It does not mean compounded GLP-1s vanished on April 30, 2026. They remain widely available, and many providers continue to dispense them.
It does not address 503A compounding directly — the bulks list at issue is the 503B one, though the earlier April 1 clarification and the 2025 deadlines affect 503A pharmacies too.
And it is not a safety finding about any individual patient’s medication. The stated basis is an absence of clinical need given that approved products are available, not a determination that compounded GLP-1s have harmed people.
What a Patient on Compounded Medication Should Do
None of this requires panic, and none of it is a reason to stop a medication abruptly. It is a reason to plan.
1. Do Not Stop Your Medication Over a News Story
Stopping a GLP-1 abruptly is a clinical decision with real consequences. Nothing in this proposal requires you to stop today. Raise it with your prescriber at your next contact instead.
2. Ask Your Provider on What Basis They Are Compounding
This is the question that matters now. Ask which pharmacy dispenses your prescription, whether it is 503A or 503B, and on what legal basis it is compounding a molecule that is on neither the shortage list nor the 503B bulks list.
3. Price the Approved Alternatives
The gap has narrowed considerably. Manufacturer channels publish self-pay pricing, an oral Wegovy formulation launched in early 2026, and Wisp publishes brand-name Wegovy from $99. Find out what approved medication would actually cost you before you need to know.
4. Check Your Insurance Again
Coverage changes, and the calculation has shifted. If a plan covers a brand-name GLP-1, an insurance-first provider can undercut every cash-pay compounded option. It is worth re-checking even if you checked a year ago.
5. Be Cautious About Long Prepayments
Annual prepaid compounded plans carry more risk in this environment than they did. If you are considering one, get cancellation and refund terms in writing, and ask specifically what happens if the provider can no longer supply.
Our Take
The direction of travel here is not ambiguous. Shortage delisting, compounding deadlines in 2025, 30 warning letters to telehealth companies, a policy clarification in April 2026, and now a proposal to formally determine there is no clinical need for outsourcing facilities to compound these molecules at all. Each step has narrowed the space further, and none has widened it.
That does not mean you should stop your medication. Compounded GLP-1s remain available, this is a proposal rather than a final rule, and abruptly stopping a GLP-1 is a clinical decision with consequences. What it means is that the assumption underpinning this entire market — cheap compounded medication indefinitely — is no longer safe to build a multi-year plan on.
The practical move is to know your alternatives before you need them. Price approved medication through LillyDirect and NovoCare Pharmacy, re-check your insurance, and look at Measured if you have any coverage worth working. Brand-name access has improved markedly in 2026 — the oral Wegovy launch and the Novo Nordisk deal with Hims & Hers both pushed approved medication toward mainstream pricing.
And ask your current provider the direct question: on what basis are you compounding this molecule now? A provider with a clear answer is worth staying with. One that will not engage with the question has told you something about how it plans to handle what comes next.
Frequently Asked Questions
Are compounded GLP-1s banned now?
No. This is a proposal, not a final rule. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, and the comment period closed on June 29, 2026. Compounded GLP-1s remain widely available, and the agency has not issued a final determination at the time of writing.
What is the 503B bulks list?
It identifies bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act. 503B outsourcing facilities are the tier that can compound at scale, and the bulks list is one route by which they may compound from a bulk substance. The FDA is proposing that these three molecules do not belong on it.
Why is the FDA doing this?
The stated basis is that it found no clinical need for outsourcing facilities to compound these drugs, given that approved versions are available and national supply has stabilised. Reuters reported the proposal as curbs on mass compounding of the Novo Nordisk and Eli Lilly weight-loss drugs.
Should I stop taking my compounded GLP-1?
Not because of this. Stopping a GLP-1 abruptly is a clinical decision with real consequences and belongs with your prescriber, not a news cycle. Raise the topic at your next contact and use the time to price approved alternatives and re-check your insurance.
Does this affect 503A pharmacies too?
The bulks list at issue is the 503B one. However, 503A pharmacies were separately affected by the shortage delisting — they had until April 22, 2025 to stop compounding semaglutide — and by the FDA’s April 1, 2026 clarification that certain conditions must be met to qualify for the 503A and 503B exemptions.
Does this include liraglutide?
Yes. The proposal covers semaglutide, tirzepatide and liraglutide. That is particularly relevant for patients considering compounded liraglutide as a route after Novo Nordisk discontinues Saxenda, with last shipments to wholesalers in late January 2027.
What should I ask my provider?
One question above all: on what basis are you compounding this molecule, given it appears on neither the FDA shortage list nor the 503B bulks list? Also ask which pharmacy dispenses your prescription and whether it is 503A or 503B. A provider with a clear answer is worth keeping; one that will not engage has told you something.
What are my alternatives if compounded access ends?
Brand-name access improved markedly in 2026. Manufacturer channels publish self-pay pricing, an oral Wegovy formulation launched in early 2026, Novo Nordisk struck a distribution agreement with Hims & Hers, and providers such as Wisp publish brand-name Wegovy from $99. If you have insurance, an insurance-first provider may undercut everything. Price these now rather than later.
Disclosure:
This article is based on publicly available FDA communications including the agency’s April 30, 2026 press announcement proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, the Federal Register notices published May 1 and June 26, 2026, the FDA’s April 1, 2026 clarification of policies for compounders, and its published statements on unapproved GLP-1 drugs, together with reporting from Reuters, CNBC, Stanford Medicine and pharmacy trade press, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. This is a plain-language summary of a developing regulatory matter and is not legal advice; the proposal described has not been finalised and its status may change. Nothing here is medical advice, and no one should start or stop a medication based on this page. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
Tirzepatide Compounding Pharmacies
Sourcing options for compounded tirzepatide compared.
Switching GLP-1 Providers
Changing provider without a treatment gap, and what to do if supply stops.
The FDA Warning Letters to GLP-1 Telehealth Companies
Thirty letters over compounded GLP-1 marketing, and how to check your provider.
Compounded GLP-1s After the Shortage Ended
What changed when semaglutide and tirzepatide left the FDA shortage list.
503A vs 503B Compounding Pharmacies
How the two categories differ, and why the distinction matters more than ever.
Best Brand-Name GLP-1 Providers
Where to get FDA-approved medication if compounded access narrows.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →